Epidemiological models for the spread of anti-malarial resistance
JC Koella*1 and R Antia2

Address: 1Laboratoire de Parasitologie Evolutive, Université P. & M. Curie, CNRS UMR 7103, 7 quai St. Bernard CC237, 75252 Paris, France and 2Department of Biology, Emory University, 1510 Clifton Road, Atlanta GA 30322, USA
Email: JC Koella* - jkoella@snv.jussieu.fr; R Antia - rantia@biology.emory.edu
* Corresponding author

Abstract
Background: The spread of drug resistance is making malaria control increasingly difficult. Mathematical models for the transmission dynamics of drug sensitive and resistant strains can be a useful tool to help to understand the factors that influence the spread of drug resistance, and they can therefore help in the design of rational strategies for the control of drug resistance.

Methods: We present an epidemiological framework to investigate the spread of anti-malarial resistance. Several mathematical models, based on the familiar Macdonald-Ross model of malaria transmission, enable us to examine the processes and parameters that are critical in determining the spread of resistance.

Results: In our simplest model, resistance does not spread if the fraction of infected individuals treated is less than a threshold value; if drug treatment exceeds this threshold, resistance will eventually become fixed in the population. The threshold value is determined only by the rates of infection and the infectious periods of resistant and sensitive parasites in untreated and treated hosts, whereas the intensity of transmission has no influence on the threshold value. In more complex models, where hosts can be infected by multiple parasite strains or where treatment varies spatially, resistance is generally not fixed, but rather some level of sensitivity is often maintained in the population.

Conclusions: The models developed in this paper are a first step in understanding the epidemiology of anti-malarial resistance and evaluating strategies to reduce the spread of resistance. However, specific recommendations for the management of resistance need to wait until we have more data on the critical parameters underlying the spread of resistance: drug use, spatial variability of treatment and parasite migration among areas, and perhaps most importantly, cost of resistance.

Background
The treatment of malaria infections and the control of the spread of malaria are made increasingly difficult by drug resistant strains of the parasite. Resistance to chloroquine, an effective and safe anti-malarial that formed the first line of treatment, emerged more than 30 years ago [1], and since then malaria parasites have developed resistance against most of the widely used anti-malarials, including sulfadoxine-pyrimethamine [2,3], mefloquine [4] and quinine [5]. Indeed, it is now generally believed that the widespread use of a new drug will inevitably be followed by the appearance of resistance in the parasite population. There is, therefore, increasing emphasis in malaria control on rational management of drug use in an...
attempt, if not to prevent, then at least to delay the spread of resistance in the parasite population. One approach is to use combination therapy, where the simultaneous use of several drugs is hoped to delay the emergence of resistance [6,7]. Another approach could be to use drugs in a mosaic fashion (temporally or spatially), so that resistance to individual drugs is counter-selected where or when the drug is not used, as is discussed for the management of antibiotic resistance [8]. However, predicting the effect of different strategies for drug use on the spread of resistance to the drug is not straightforward because of the complex interactions that determine the transmission of the parasite between human and mosquito populations. Mathematical models have in the past provided a valuable framework for analysing the transmission dynamics of malaria [9,10]. These models have been widely used to consider the effect of different strategies such as vector control [11] and the use of future vaccines on the transmission dynamics of malaria [12,13].

In this paper, we extend these models to investigate the spread of drug resistance in malaria. We develop models of malaria transmission that allow us to examine the simplest case: the spread of resistance to a single drug, encoded at a single genetic locus. We modify standard epidemiological models of malaria transmission to incorporate drug sensitive and drug resistant parasite populations, and use this model to investigate the conditions under which drug resistance will spread in the population of hosts, as well as to predict the rate of spread of resistance. We then examine how superinfection or heterogeneity in treatment will modify the earlier results.

Our epidemiological models provide a counterweight to the recent models based on population genetic considerations [14–16]. One of the purposes of the paper is thus to discuss the similarities and differences in the predictions of the genetic and epidemiological models. But our main aims are to find which parameters would be necessary to predict the spread of resistance and to emphasize our lack of knowledge about any of these parameters.

Models

Epidemiological framework

Our models are based on previously published extensions of the classical Macdonald-Ross model, which take into account acquired immunity by humans and allow the duration of immunity to depend on exposure (i.e. that immunity is boosted by additional infections) [17,18]. Though the assumptions about the development of immunity are undoubtedly overly simple, the model can predict several important epidemiological patterns, e.g. that the crude prevalence of malaria in a population may decrease at very high levels of transmission [19,20]. Furthermore, variations of the model (where immunity is life-long or where the duration of immunity is constant, rather than being boosted by new infections) gave similar predictions, so that our results are robust with respect to details of the dynamics of immunity.

The human population is split into a proportion $x$ of susceptibles, a proportion $y$ of infecteds and a proportion $z$ of immunes (Fig. 1). The changes in the proportions of these three categories are described by three differential equations:

$$\frac{dx}{dt} = \delta - \delta x - hx + pz$$
$$\frac{dy}{dt} = hx - (r + \delta)y$$
$$\frac{dz}{dt} = ry - (\rho + \delta) z$$

(S1)

Susceptibles become infected at the inoculation rate $h$ (which is derived below). Infected individuals recover at a rate $r$ to become immune, and immunes lose their immunity and become susceptible again at a rate $p$. Deaths occur at a rate $\delta$ (i.e. the life-expectancy is $1/\delta$) and are not affected by disease status. Deaths are balanced by births into the susceptible class, so that the population size remains constant.

If the duration of immunity is $\omega$ years in the absence of new infections and immunity is boosted by re-exposure,
reference [20] shows that the rate at which immunity is lost can be set to

$$\rho = \frac{(h + \delta) e^{-(h+\delta)\omega}}{1 - e^{-(h+\delta)\omega}} \quad (2)$$

Consider next the infection rate of mosquitoes. The mosquito population is split into three categories: a proportion $v$ of infected mosquitoes that have not yet developed infectious sporozoites, a proportion $w$ of infectious individuals with sporozoites in the salivary glands, and a proportion $1 - v - w$ of uninfecteds. Susceptible mosquitoes become infected by biting infected humans at a rate $a$; only a proportion $b$ of the bites lead to infection. Thus the proportion of infected mosquitoes increases at a rate $aby(1 - v - w)$. The newly infected mosquitoes become infectious to humans, if they survive the incubation period, $\tau$, required for the development of the parasite. Assuming a mortality rate $\mu$, a proportion $e^{-\mu \tau}$ survives this period. Thus, of the $aby(1 - v - w)$ mosquitoes infected $\tau$ days earlier, $aby(1 - v - w)e^{-\mu \tau}$ move from the latent to the infectious state. The proportions of latent and infectious mosquitoes decrease through mortality. The process of infection can thus be summarized as

$$\frac{dv}{dt} = aby(1 - v - w) - ab\hat{y}(1 - \hat{v} - \hat{w})e^{-\mu \tau} - \mu v \quad (3)$$
$$\frac{dw}{dt} = ab\hat{y}(1 - \hat{v} - \hat{w})e^{-\mu \tau} - \mu w$$

where $\hat{v} \equiv v(t - \tau)$, $\hat{w} \equiv w(t - \tau)$ and $\hat{w} \equiv w(t - \tau)$.

Because the mosquito dynamics operate on a much faster time-scale than the human dynamics described by equation (1), the mosquito population can be considered to be at equilibrium with respect to changes in the human population. This allows its dynamics to be collapsed into the inoculation rate $h$:

$$h = mba^2 e^{-\mu \tau} \frac{y}{\mu + aby} \quad (4)$$

where $m$ denotes the number of mosquitoes per human.

As is customary for epidemiological models, transmission is summarized by the basic reproductive number, which gives the number of secondary cases following introduction of a single infected individual into a susceptible population.

$$R_0 = \frac{mba^2 e^{-\mu \tau}}{(r + \delta)\mu} \quad (5)$$

As an indicator of the intensity of transmission, $R_0$ will tend to be increased by natural selection, and parasites with higher $R_0$ will invade populations of parasites with lower reproductive numbers.

**Spread of resistance**

The basic model can easily be extended to describe the spread of resistant parasites. We assume that resistance is conferred by an allele at one locus, so that we can consider the spread of resistance as competition among two strains of parasites, an anti-malarial sensitive and a resistant one. We further assume that a fraction $f$ of the infected individuals is treated. With these assumptions, the compartment model of Figure 1 is changed to allow for three sub-compartments of infected individuals: hosts that are infected with the sensitive strain but that are not treated, hosts infected with the sensitive strain and treated, and hosts infected with the resistant strain, which is not affected by treatment (Fig. 2). With the subscripts $S$ and $R$ denoting sensitive and resistant strains, respectively, and the subscripts $U$ and $T$ denoting untreated and treated infections, equations (1) are modified to

$$\frac{dx}{dt} = \delta - \delta x - (h_S + h_R)x + \rho z$$
$$\frac{dy_{ST}}{dt} = fh_S x - (r_{ST} + \delta)y_{ST}$$
$$\frac{dy_{SU}}{dt} = (1 - f)h_S x - (r_{SU} + \delta)y_{SU}$$
$$\frac{dy_R}{dt} = h_R x - (r_R + \delta)y_R$$
$$\frac{dz}{dt} = r_{ST} y_{ST} + r_{SU} y_{SU} + r_R y_R - (\rho + \delta)z \quad (6)$$

The inoculation rates of sensitive and resistant parasites can be calculated as

$$h_S = mba^2 e^{-\mu \tau} \frac{y_S}{\mu + a(y_S + y_R)}$$
$$h_R = mba^2 e^{-\mu \tau} \frac{y_R}{\mu + a(y_S + y_R)} \quad (7)$$

where $y_S = y_{ST} + y_{SU}$. The inoculation rate of the resistant parasites can be written as
\[ h_R = \frac{1}{\gamma_t} \frac{\gamma_R}{\gamma_S} h_S \]  

where \( \gamma_t = \frac{b_S}{b_R} \) is the change of transmission due to a change from sensitivity to resistance; it denotes the transmission cost of resistance. Note that, although we have modelled the transmission cost in terms of infectivity from the human to the mosquito, the cost can also be expressed in terms of other transmission parameters. Mosquitoes harbouring resistant parasites, for example, may bite less frequently or experience higher mortality than those infected with sensitive parasites.

We further assume that the differences in recovery rate are due to treatment and to a cost of resistance within the human host. Therefore

\[ r_{SU} < r_R < r_{ST} \]  

We can estimate the relative transmission of the sensitive and resistant parasites with their basic reproductive numbers. Letting equation (5) denote the basic reproductive number of the untreated, sensitive parasites and assuming that the average life-span of humans is considerably greater than the duration of infection \( (1/\delta >> 1/r_{SU}) \), the basic reproductive number of the sensitive parasites (in the absence of resistant ones) becomes

\[ R_S = R_0 \left[ 1 - f \left( 1 - \frac{r_{SU}}{r_{ST}} \right) \right] \]  

where \( R_0 \) equals the basic reproductive number defined in equation (5), i.e. for sensitive parasites in the absence of treatment. The basic reproductive number of the sensitive infections declines linearly with increasing treatment. In the absence of resistance treatment can eradicate the disease, if it drives the basic reproductive number to less than unity, i.e. if the fraction of infections treated is larger than a critical value \( f_c \) given by:

\[ f_c = \left( 1 - \frac{1}{R_0} \right) \left( \frac{r_{ST}}{r_{ST} - r_{SU}} \right) \]  

If we introduce resistant parasites, the outcome depends on the relative magnitude of the basic reproductive numbers of the sensitive and resistant infections. The latter is given by

\[ R_R = \frac{1}{\Gamma} R_0 \]  

where \( \Gamma = \gamma_t r_R / r_{SU} \) describes the reduction of the intensity of transmission due to a switch from sensitivity to resistance and can therefore be defined as the total cost of resistance. The long-term outcome will depend on whether \( R_R \) is larger than \( R_S \), which in turn depends on whether the proportion of individuals receiving treatment exceeds a threshold \( f_c \) defined as

\[ f_c = \frac{1 - \frac{1}{\Gamma}}{1 - \frac{r_{SU}}{r_{ST}}} \]  

If the proportion of treated individuals is less than the threshold \( f_c \), \( R_S > R_R \) and all parasites in the population remain sensitive. If the proportion of treated individuals is higher than \( f_c \), all parasites will eventually become resistant. Note that this proportion depends only on two parameters: the cost of resistance and the ratio of the periods of infection in treated and untreated individuals. In particular, the threshold proportion is independent of the
intensity of transmission (measured as $R_0$, the basic reproductive number of the sensitive strain in the absence of treatment). Similarly, the rate at which resistance spreads, once the threshold proportion of treatment is exceeded, depends largely on the frequency of treatment and the cost of treatment, but is almost independent of the intensity of transmission (Fig. 3).

Thus, in this model, there is competitive exclusion between resistant and sensitive parasites. Whether sensitivity or resistance predominates in the population depends on three parameters: (i) the proportion of infected individuals that receive treatment, (ii) the effectiveness of treatment defined in terms of period of infection as $e = 1 - r_{SU}/r_{ST}$, and (iii) the cost of resistance.

Superinfection of hosts

In the previous model we assumed that hosts cannot be superinfected by a second parasite, which would lead to a mixture of sensitive and resistant parasites in the same patient. In this section we relax this assumption and allow superinfection of hosts, assuming that sensitive and resistant parasites develop independently within their host. We further assume that the treatment has a short half-life, so that the decision to treat superinfections is independent of any earlier treatment. In other words, a proportion $f$ of all superinfections will be treated, while a proportion $1 - f$ will not be treated, irrespective of whether the first infection was treated or not. (We also analyzed a model where the treatment has a long-life and where the superinfecting parasite therefore receives the same treatment as the first infection. In this case, treated individuals cannot be superinfected with a sensitive parasite. The conclusions are the same as the ones reached with the equations given here). With these assumptions equations (6) can be modified to

$$
\frac{dx}{dt} = \delta - \delta x - (h_s + h_u)x + \rho z
$$

$$
\frac{dy_{ST}}{dt} = \beta_{x} - (\gamma_{ST} + \delta) y_{ST} - h_{ST} y_{ST} + \rho y_{MT}
$$

$$
\frac{dy_{SU}}{dt} = (1 - f) \beta_{x} - (\gamma_{SU} + \delta) y_{SU} - h_{SU} y_{SU} + \rho y_{MT}
$$

$$
\frac{dy_{R}}{dt} = \beta_{x} - (\gamma_{R} + \delta) y_{R} - h_{R} y_{R} + \gamma_{ST} y_{ST} + \gamma_{SU} y_{SU}
$$

$$
\frac{d\gamma_{MT}}{dt} = \beta_{y} (y_{SU} + y_{ST}) + \rho y_{MT} - (\gamma_{ST} + \gamma_{R} + d) y_{MT}
$$

$$
\frac{dy_{SU}}{dt} = (1 - f) \beta_{y} (y_{SU} + y_{ST}) + (1 - f) h_{R} y_{R} - (\gamma_{SU} + \gamma_{R} + \delta) y_{SU}
$$

$$
\frac{dy_{R}}{dt} = (1 - f) \beta_{y} (y_{SU} + y_{ST}) + (1 - f) h_{R} y_{R} - (\gamma_{SU} + \gamma_{R} + \delta) y_{R}
$$

(14)

where the subscript $M$ denotes mixed infections. The inoculation rates of sensitive and resistant parasites are changed accordingly as

$$
h_{S} = mb_{S} a^{e^{-\mu t}} \frac{y_{S} + y_{M}}{\mu + a} \left[ b_{S} (y_{S} + y_{M}) + b_{R} (y_{R} + y_{M}) \right]
$$

$$
h_{R} = mb_{R} a^{e^{-\mu t}} \frac{y_{R} + y_{M}}{\mu + a} \left[ b_{S} (y_{S} + y_{M}) + b_{R} (y_{R} + y_{M}) \right]
$$

(15)

where $y_{S} = y_{ST} + y_{SU}$ and $y_{M} = y_{MT} + y_{MU}$.

With this model the parasite population switches from being predominantly sensitive to being predominantly resistant at a similar frequency as in the model without superinfection (defined by equation 13). The main difference due to superinfection is that competitive exclusion is not always achieved. At intermediate levels of treatment resistant and sensitive parasites can coexist in the same population (Fig. 4). The area where coexistence is possible increases as the cost of resistance decreases. Furthermore, if the cost is sufficiently low, resistance can invade a sensitive population even when there is no treatment, so that
resistant parasites are found in the absence of any treatment.

The possibility of coexistence of two parasite strains comes as no surprise. In many models of epidemiology, superinfection allows the coexistence of many strains, and in particular the coexistence of strains with considerable differences of transmission success [21].

Spatial variability in treatment rates
In this section, we relax a further assumption of the basic model: that drug treatment is applied uniformly to a population of hosts. In a natural situation, it is more likely that treatment levels will vary among host individuals and among host populations. We therefore ask, to what extent will gene flow via migration counteract the selective forces due to treatment in a local environment? To do so, we extend the model defined by equations (6) and (7) by assuming that the gene flow is due to migration of the mosquito vectors infected by sensitive or resistant parasites.

We will consider two cases. First, following work by Comins [22] we assume that there is a reservoir of untreated humans, where all parasites are sensitive. In the treated area, infection will be due partly to parasites surviving the treatment in this area and partly to parasites that have migrated from the untreated into the treated area. Second, we consider several human populations with differing treatment rates. Infected vectors migrate among neighbouring populations, so that they can migrate from the treated area to the untreated one.

In the first of these possibilities we assume that the epidemiology in the untreated area follows the basic model formulated in equations (1)-(4), and that the epidemiology in the treated area is determined by the competition between the resistant and the sensitive strains according to equations (6) and (7). The equations are modified, so that a proportion $m$ of the infected mosquitoes migrates from the untreated area to the treated one. In this case the migration of sensitive parasites into the treated area prevents the selection of resistance, if the migration rate and the cost of resistance are high enough (Fig. 5). For lower migration rates, resistance in the treated area increases towards an intermediate level, which is often close to fixation. These results are similar to those obtained previously [22] for the evolution of insecticide resistance.

In the more general case, migration from the treated area into the untreated zone will not be negligible. We model this situation by incorporating two areas that are identical except for their levels of treatment; in one area all infections are treated, in the other none are. In both, the epidemiology is modelled according to equations (6) and (7), and a proportion $m$ (which is independent of area or resistance) of the infected mosquitoes migrates from one area to the other. At sufficiently low migration rates the two areas behave independently, with competitive exclusion within each area; sensitive parasites predominate in the untreated area (Fig. 6a) and resistant ones predominate in the treated area (Fig. 6b). At intermediate migration rates, competitive exclusion between sensitive and resistant parasites may break down. The level of resistance maintained in either area depends on the combination of the migration rate and the cost of resistance. A migration rate of 0.5 corresponds to a well-mixed population where half of the infections are treated. If migration rates exceed this value, the population as a whole is either completely sensitive or completely resistant; competitive exclusion operates at the level of the meta-population.

Discussion
Summary of results
Our models enable us to explore the consequences of changing the level of drug use on the frequency of resistant malaria parasites. In the simplest model, we find a
threshold level of drug use, below which resistance cannot spread and above which resistance spreads and eventually becomes fixed. The threshold level is determined by the extent to which treatment of sensitive parasites reduces their duration of infection and by the cost of resistance, which is defined by the transmissibility of resistant parasites and by their duration of infection relative to untreated infections with sensitive parasites. This competitive exclusion between sensitive and resistant infections arises, because the parasite with the higher basic reproductive number $R_0$ drives the number of susceptible hosts below the threshold density that would be necessary to maintain the parasite with the lower basic reproductive number [23]. This result is the counterpart to earlier studies on the spread of resistance in directly transmitted infections [8]. It reflects that resistance is detrimental to the transmission of the parasite in untreated hosts, but beneficial in treated individuals, so that increasing drug use beyond a critical threshold tips the balance from 0% to 100% prevalence of resistance.

Allowing infection of hosts with both types of parasite gives similar results. The main differences are that, under some combinations of parameters, the resistant and sensitive parasites can coexist and that, for a low cost of resistance, resistant parasites can coexist with sensitive ones in the absence of treatment. This reflects the general conclusion that superinfection can maintain several parasite strains with different basic reproductive numbers [21]. The parasite with low transmission success can infect hosts that are already infected by the more rapidly transmitted parasite. Therefore, evolution does not lead to competitive exclusion and does not maximize transmission, in contrast to models without superinfection.

Spatial variability in treatment rates can have a larger effect on the spread of resistance. High migration between areas with and without treatment can swamp the local effects of selection. Thus, when the cost of resistance is high, sensitive parasites can dominate in areas where every host receives treatment; when the cost of resistance is low, all parasites in areas where no treatment is available can become resistant. At intermediate costs of resistance and migration rates, coexistence of sensitive and resistant parasites is possible within each area. This coexistence arises as a balance between selection within the populations and migration between populations. Migrants (with the inappropriate type) can persist for some time before they are removed by selection (drug pressure or the cost of resistance) occurring within each population. Therefore, at some ratios of migration and selection, both types of parasites can coexist.

Thus, from the small number of models described here, it is clear that knowledge about several parameters is critical for our understanding of the spread of resistance: the drug use, the spatial variability of treatment and parasite migration among areas, and perhaps most importantly, the cost of resistance.

**Any data?**
Unfortunately, data on any of these parameters are very limited, and almost completely restricted to chloroquine. Even data on the use of chloroquine, which may seem to be the easiest data to get, are poor. Though we may be able to estimate the total drug use in an area (e.g. 191 tons of chloroquine in Africa in 1988 [24]), though we may also obtain the consumption of the drug in an area (e.g. in endemic areas, large proportions of children have chloroquine residues in their blood at any given time [25]) and estimate the number of patients with clinical malaria receiving the drug, the more critical questions are: What proportion of infected people (as opposed to sick people) receive treatment, and is the dose of the drug sufficient to clear the parasites?
That resistance, at least against chloroquine, is costly in terms of transmission is suggested by the observation that resistance has dropped significantly in several areas when chloroquine was no longer used. In contrast, however, some data suggest that resistance is associated with a benefit, rather than a cost, in terms of transmission from humans to mosquitoes [26–28]. This is supported by in vitro studies of parasite development showing that resistant parasites grow more slowly than sensitive parasites, but develop their transmission stages earlier and at a higher rate [29]. However, additional factors must balance and outweigh this apparent benefit of resistance, otherwise resistance would have spread before the wide-spread use of drugs. The genetic basis for the spread is given. Even before the use of a drug, resistance is present at low levels in many populations, in particular for quinine and proguanil [30]. This probably applies for chloroquine as well, although the data are less convincing [31]). Possible factors leading to a cost of resistance might be related to the mortality of infected mosquitoes, since the parasite's transmission rate is more sensitive to mosquito mortality than to the effectiveness of transmission from humans to mosquitoes [9]. Thus, the more effective transmission from humans to mosquitoes could be more than compensated by the higher mortality of heavily infected mosquitoes [32,33]. Overall, there is some qualitative evidence for a cost of resistance, although quantitative measures of such a cost are absent.

**Critique of the models**

Obviously, like other mathematical (or non-mathematical) models, our equations are simple caricatures of the epidemiological processes being considered. The success of a model will depend on the inclusion of the relevant processes. There are several reasons for believing that the models we propose capture some aspect of reality. Compartment models of infectious diseases in general have had considerable success in epidemiology [34]. In particular, compartment models similar to the ones used here can describe several epidemiological patterns of malaria [11], including, for example, the observation that increased transmission can decrease the malaria prevalence.

**Figure 6**

Effect of spatial variability in treatment levels on the spread of resistance. The model underlying this graph assumes an area of untreated individuals ($f = 0$) and an area where all hosts are treated ($f = 1$), with migration of mosquitoes between both areas. The proportions of resistant parasites at equilibrium in (a) the untreated area and (b) the treated area are given as a function of the cost of resistance (defined by equation 12) and the proportion of mosquitoes migrating from one area to the other. The parameters are as in Fig. 4.
among adults of a population [20]. Similar models are considered helpful in evaluating the sensitivity of malaria transmission to different control measures [9] and in predicting the effectiveness of vaccine programmes [13,35]. Compartment models have also been used to examine the epidemiology of antimicrobial resistance in acute infections [8] as well as hospital acquired infections [36] and specific infections such as tuberculosis [37] and HIV [38]. The current paper is a first attempt at applying them to anti-malarial resistance.

There are a number of specific problems with modelling the epidemiology of resistance to malaria, which we briefly discuss below. One set of problems concerns the epidemiological processes of malaria. In this category are problems associated with the lack of our understanding of the nature of immunity to malaria at the individual and epidemiological levels. Thus, the equations describing the development of immunity reflect the true process only crudely. However, simulations with two extreme alternative models (life-long immunity after the first infection or immunity without boosting, i.e. that is lost at a constant rate) suggest that our results are insensitive to the details of the immunological process. Furthermore, we have assumed that treatment does not affect the development of immunity. While we have no data on this issue for malaria, it is a reasonable assumption that is based on observations in other systems. The T-cell response to bacteria, for example, is programmed early in an infection (before the peak of the inflammatory response) and independent of the duration and severity of the bacterial infection. In other words, the infection starts the program, but has little influence on the further development of the immune response [39].

A second set of problems is associated with the genetics of malaria parasites. In this category falls the possibility that malaria is structured in distinct strains [40,41]. This could slow the evolution of drug resistance if resistance is due to several genetic loci [15]. This model and other models that take into account details of population genetics [14–16], as have population genetic models of the resistance of other parasites [34], show the importance and uses of population genetics. However, just as our equations neglect population genetics, these models have neglected the epidemiological processes underlying the evolutionary changes. From our models it appears that the neglect of epidemiology could qualitatively bias the results; the differences between competitive exclusion and coexistence, for example, can only be reached by explicitly contrasting different epidemiological assumptions and settings. Perhaps the best approach would be to merge epidemiological and genetic models. This approach has been taken several times in the recent literature with models taking into account individual infections [42–44], but it has some major disadvantages. Most importantly, because of the complexity of the models some important epidemiological features must be omitted. These models have not (or only in basic terms) taken account of acquired immunity, which is an important aspect of malaria epidemiology. If merging transmission and genetics is too complex, it remains to be seen whether focusing on the genetic side or on the epidemiological side will lead to better predictions. Certainly, where the genetics are simple (one locus), the epidemiological approach is more promising.

Conclusions

The approach offered here can provide insights into several aspects of the epidemiology of anti-malarial resistance. It remains unclear why chloroquine resistance has emerged much later in sub-Saharan Africa than in South-East Asia [24]. This fact is often attributed to the high transmission in Africa, with the assumption that high transmission (and therefore strong acquired and innate immunity) leads to a slow spread of resistance [31]. This assumption has indeed been found in some models of the spread of resistance, because intense transmission is associated with less inbreeding, which in turn can lead to slower spread of resistance under some conditions [15,16]. However, this prediction is not universal, but depends on the details of the assumptions underlying transmission. Thus our model predicts either little or the opposite effect of transmission rate, while another recent model [45] shows that the within-host dynamics of malaria help to determine whether resistance is more likely to emerge in areas with high or with low transmission. But perhaps the explanation is much simpler: the use of chloroquine was fairly low until the mid-70s [24], so that resistance would be maintained at a low level due to the cost of resistance. As the chloroquine consumption increased to a peak of 191 tons in 1988 [24], it brought a rapid increase of resistance. Unfortunately, we do not have the quantitative data required to explore this possibility in more detail.

A further puzzle is that pyrimethamine resistance often spreads to areas not submitted to pyrimethamine pressure [46]. One unlikely explanation is that resistance is associated with a benefit, rather than a cost. Another explanation could be that resistance spreads from areas with high drug consumption, provided the migration rate is sufficiently high and the cost of resistance is low.

Similarly, there appears to be a low, but non-negligible level of resistance in most geographical areas even before exposure to drugs [31]. A possible explanation for this is a balance between mutation and selection [16], but it might also be explained by superinfection, which allows resis-
ance to be maintained at low levels in areas in the absence of treatment, if resistance is not too costly.

Overall, an epidemiological approach could lead to valuable insights into the spread of resistance. What is needed is, on the one hand, investigation of the processes determining the spread and, on the other hand, more detailed knowledge of the critical parameters involved, e.g. cost of resistance. Only this will enable us to give advice about rational drug management that could slow the spread of resistance.

Authors’ contributions

The authors contributed equally to the formulation of the models. JK undertook the calculations. Both authors edited, read and approved the final manuscript. RA acknowledges support from the NIH (R29-GM-54268 and Al 49334).

Acknowledgements

We thank several reviewers of previous versions of the manuscript for their helpful comments.

References

1. Moore DV and Lanier JE Observations on two Plasmodium falciparum infections with abnormal response to chloroquine. Am J Trop Med Hyg 1961, 10:5-9
2. Hakim SL, Roohi SWAS, Zurkurnai Y, Rain AN, Mansor SM, Palmer K, Navaratnam V and Mak JW Plasmodium falciparum – increased proportion of severe resistance (RII and RIII) to chloroquine and high rate of resistance to sulfadoxine-pyrimethamine in peninsular Malaysia after 2 decades. Trans R Soc Trop Med Hyg 1996, 90:294-297
3. Smithius FM, Monti F, Grundl M, Oo AZ, Kyaw TT, Pho O and White MJ P. falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar. Trans R Soc Trop Med Hyg 1997, 91:468-472
4. Mockenhaupt F Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995, 11:248-253
5. Benito A, Roche J, Molina R, Amela C and Alvar J In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea. Am J Trop Med Hyg 1995, 53:526-531
6. White NJ Delaying antimalarial drug resistance with combination chemotherapy. Parasitologia 1999, 41:301-8
7. White N Antimalarial drug resistance and combination chemotherapy. Phil Trans R Soc London B Biol Sci 1999, 354:739-49
8. Bonhoeffer S, Lipsitch M and Levin BR Evaluating treatment protocols to prevent antibiotic resistance. Proc Nat Acad Sci USA 1997, 94:12106-12111
9. Macdonald G The Epidemiology and Control of Malaria. London: Oxford University Press 1957.
10. Dietz K, Molinaux L and Thomas A A malaria model tested in the African savannah. Bull World Hlth Assoc 1974, 50:347-357
11. Molinaux L and Gramiccia G The Garki Project: Research on the Epidemiology and Control of Malaria in the Sudan Savanna of West Africa. Geneva: World Health Organization 1980.
12. Halloran ME and Struchiner CJ Modeling transmission dynamics of stage-specific malaria vaccines. Parasitol Today 1992, 8:77-85
13. Gupta S and Anderson RM Predicting the effects of malaria vaccines on the population dynamics of infection and disease. In: Malaria Vaccine Development: A Multi-Immune Response Approach (Edited by: Hoffman SL) Washington DC: ASM Press 1996, 524-276
14. Curtis CF and Otto LN A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg 1986, 80:889-892
15. Dye C and Williams BG Multigenic drug resistance among inbred malaria parasites. Proc R Soc London Ser B Biol Sci 1997, 264:61-67
16. Hastings IM A model for the origins and spread of drug resistant malaria. Parasitology 1997, 115:133-141
17. Aron JL Acquired immunity dependent upon exposure in an SIRS epidemic model. Math Biosc 1988, 88:37-47
18. Aron JL Mathematical modeling of immunity to malaria. Math Biosc 1988, 90:385-396
19. Boyd MF Epidemiology: factors related to the definitive host. In: Malaria: A Comprehensive Survey of all Aspects of this Group of Diseases from a Global Standpoint (Edited by: Boyd MF) Philadelphia: W.B. Saunders 1949, 1608-1630
20. Aron JL and May RM The population dynamics of malaria. In: The Population Dynamics of Infectious Diseases: Theory and Applications (Edited by: Anderson RM) London: Chapman and Hall 1982, 139-179
21. Nowak MA and May RM Superinfection and the evolution of the multiple virulence. J theor Biol 1989, 131:49-57
22. Comins HN The development of insecticide resistance in the presence of migration. J theor Biol 1977, 64:177-197
23. Bremermann HJ and Thieme HR A competitive-exclusion principle for pathogen virulence. J math Biol 1989, 27:179-190
24. Wessendorfer VH The development and spread of drug-resistant malaria. Parasitol Today 1991, 7:297-303
25. Kilombero Malaria Project: Household based malaria control in a highly endemic area of Africa (Tanzania): determinants of transmission and disease and indicators for monitoring. Memorias do Instituto Oswaldo Cruz 1992, 87:121-130
26. Handunnetti SM, Gunewardena DM, Pathirana PPSL, Ekanayake Y, Weerasinghe S and Mendis KN Features of recrudescence chloroquine-resistant Plasmodium falciparum infections confer a survival advantage on parasites and have implications for disease control. Trans R Soc Trop Med Hyg 1996, 90:563-567
27. Ichimori K, Curtis CF and Targett GAT The effects of chloroquine on the infectivity of chloroquine-sensitive and -resistant populations of Plasmodium yoelii nigeriensis to mosquitoes. Parasitology 1990, 100:377-387
28. Robert V, Molez J-F and Trape J-F Short report: gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in West Africa. Am J Trop Med Hyg 1996, 55:350-351
29. Koella JC Linking evolution and ecology with epidemiology. Rev Suisse Zool 1994, 101:865-874
30. Peters W Chemotherapy and Drug Resistance in Malaria. London: Academic Press 1987.
31. Molinaux L The epidemiology of drug resistance in malaria: an unfinished conceptual model. WHO informal consultation on the epidemiology of drug resistance of malaria parasites 1986. Working paper 2.7.1:
32. Anderson RA, Knols BJG and Koella JC Plasmodium falciparum sporozoites increasing feeding-associated mortality of their mosquito hosts Anopheles gambiae s.l. Parasitology 2000, 120:329-333
33. Klein TA, Harrison BA, Grove JS, Dixon SV and Andre RG Correlation of survival rates of Anopheles dirus A (Diptera: Culicidae) with different infection densities of Plasmodium cynomolgi. Bull Wld Hlth Assoc 1986, 64:901-907
34. Anderson RM and May RM Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press 1991.
35. Koella JC On the use of mathematical models of malaria transmission. Acta Trop 1991, 49:1-25
36. Lipsitch M, Bergstrom CT and Levin BR The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Nat Acad Sci USA 2000, 97:1938-1943
37. Blower SM, Small PM and Hopewell PC Control strategies for tuberculosis epidemics: new models for old problems. Science 1996, 273:497-500
38. Blower SM, Aschenbach AN, Gershenhorn HB and Kahn JO Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001, 7:1016-20
39. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM and Pamer EG Early programming of T cell populations responding to bacterial infection. J Immunol 2000, 165:6833-9
40. Gupta S, Maiden MCJ, Feavers IM, Nee S, May RM and Anderson RM The maintenance of strain structure in populations of recombining infectious agents. Nature Med 1996, 2:437-442
41. Tibayrenc M and Ayala F. Towards a population genetic theory of micro-organisms: the clonal theory of parasitic protozoa. Parasitol Today 1991, 7:228-232
42. Cross AP and Singer B. Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. Trans R Soc Trop Med Hyg 1991, 85:349-355
43. Dye C. Population genetics of nonclonal, nonrandomly mating malaria parasites. Parasitol Today 1991, 7:236-240
44. Dye C. Models for investigating genetic exchange in protozoan populations. In: Modelling Vector-borne and Other Parasitic Diseases (Edited by: Perry BD, Hansen JW) Nairobi: ILRAD 1994, 165-176
45. Hastings IM and Mackinnon MJ. The emergence of drug-resistant malaria. Parasitology 1998, 117:411-417
46. Clyde DF. Malaria in Tanzania. Oxford: Oxford Univerity Press 1967.